Clinical Trial Update: Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide [NA]

View source ↗

Summary

A clinical trial evaluating an exercise intervention for patients with metastatic castration-resistant prostate cancer receiving abiraterone or enzalutamide has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC) | NA | Status: WITHDRAWN